Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 129 clinical trials
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

SUNNIFORECAST (Sunitinib vs. Nivolumab + Ipilimumab as First line treatment Of REnal cell CAncer of non-clear cell SubTypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell …

platelet count
measurable disease
University Hospital Erlangen
 (8.7 away) Contact site
  • 25 Jan, 2021
  • +40 other locations
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

left bundle branch block
cardiac resynchronization therapy
medical therapy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 16 Feb, 2021
  • +68 other locations
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

progressive disease
measurable disease
radionuclide therapy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 23 Sep, 2021
  • +83 other locations
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs. A side effect is anything the drugs do besides treating cancer. Pembrolizumab is a drug that can be used to treat triple-negative …

breast cancer
advanced breast cancer
stage iv breast cancer
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 23 Aug, 2021
  • +59 other locations
Randomization of Single vs Multiple Arterial Grafts

The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge …

myocardial infarction
bypass graft
bypass surgery
University Hospital Erlangen
 (9.4 away) Contact site
  • 28 May, 2021
  • +56 other locations
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score 2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral …

anticoagulation therapy
Universit tsklinikum Erlangen, Medizinische Klinik II - Kardiologie und Angiologie
 (8.7 away) Contact site
  • 05 Aug, 2021
  • +43 other locations
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.

Novartis Investigative Site
 (8.7 away) Contact site
  • 26 Jan, 2021
  • +48 other locations
Study of Intratumoral CV8102 in cMEL cSCC hnSCC and ACC

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

malignant melanoma of skin
measurable disease
non-melanoma skin cancer
squamous cell carcinoma
Investigative Site
 (9.4 away) Contact site
  • 13 Aug, 2021
  • +59 other locations
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients are …

Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 04 Sep, 2021
  • +39 other locations
A Multicentre European Study to Evaluate Granulox Used in the Treatment Pathway of Predominantly Chronic Venous Leg Ulcers (VLUs).

The investigation is designed as an open label, randomized, prospective, assessor blinded, multi centre investigation. 254 evaluable subjects will be randomized to either standard of care group or standard of care with Granulox added as an adjunct therapy in predominantly venous leg ulcer subjects. Standard of care wound management will …

venous insufficiency
compression therapy
systemic steroids
foot ulcer
leg ulcer
University Hospital Erlangen
 (9.4 away) Contact site
  • 08 May, 2021
  • +36 other locations